Tag
LifeBioSciences has dosed the first patient in a Phase 1 trial of ER-100, an epigenetic restoration drug candidate for optic neuropathies, marking a milestone in the development of therapies for vision impairment.
First person treated in a gene therapy trial using partial reprogramming to rejuvenate cells, aiming to treat glaucoma by regenerating optic nerve neurons.
Researchers developed an electronics-free smart contact lens using microfluidics to continuously monitor eye pressure and automatically release glaucoma medication when needed, achieving 94% accuracy with a phone-based imaging app.